| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Luoxin Pharmaceuticals Group Stock Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥4.63 |
| 52 Week High | CN¥7.00 |
| 52 Week Low | CN¥3.41 |
| Beta | 0.52 |
| 1 Month Change | 1.98% |
| 3 Month Change | 19.02% |
| 1 Year Change | -33.19% |
| 3 Year Change | -52.76% |
| 5 Year Change | n/a |
| Change since IPO | -67.87% |
Recent News & Updates
Shareholder Returns
| 2793 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 7.2% | 2.7% | 1.2% |
| 1Y | -33.2% | -10.9% | -12.6% |
Return vs Industry: 002793 underperformed the CN Pharmaceuticals industry which returned -10.9% over the past year.
Return vs Market: 002793 underperformed the CN Market which returned -12.6% over the past year.
Price Volatility
| 2793 volatility | |
|---|---|
| 2793 Average Weekly Movement | 8.6% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CN Market | 12.1% |
| 10% least volatile stocks in CN Market | 5.0% |
Stable Share Price: 002793 has not had significant price volatility in the past 3 months.
Volatility Over Time: 002793's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 4,582 | Baoqi Liu | www.luoxin.cn |
Luoxin Pharmaceuticals Group Stock Co., Ltd. engages in the research and development, manufacture, and trading of drugs in China. The company provides antiviral, anti-infective, respiratory and digestive system, nervous and endocrine system, cardiovascular system, oncology, and anti-allergic APIs and intermediates, as well as antipyretic, analgesics, and anti-inflammatory APIs and intermediates.
Luoxin Pharmaceuticals Group Stock Co., Ltd. Fundamentals Summary
| 2793 fundamental statistics | |
|---|---|
| Market cap | CN¥5.04b |
| Earnings (TTM) | -CN¥607.56m |
| Revenue (TTM) | CN¥2.39b |
2.1x
P/S Ratio-8.3x
P/E RatioIs 2793 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2793 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.39b |
| Cost of Revenue | CN¥1.35b |
| Gross Profit | CN¥1.04b |
| Other Expenses | CN¥1.65b |
| Earnings | -CN¥607.56m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.56 |
| Gross Margin | 43.47% |
| Net Profit Margin | -25.42% |
| Debt/Equity Ratio | 70.2% |
How did 2793 perform over the long term?
See historical performance and comparison